October 20–22, Abu Dhabi
Insilico Medicine will make an appearance at the Abu Dhabi Future Health Summit, held at the Abu Dhabi National Exhibition Centre (ADNEC) from October 20 to 22, and will welcome visitors at Booth 3A00. Through this event, Insilico Medicine looks forward to engaging in deep exchanges with global partners on cutting-edge developments in AI-driven drug discovery, showcasing innovative applications of generative AI across the entire lifecycle of new drug R&D, and actively exploring multi-dimensional strategic collaboration opportunities.
Additionally, Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will participate in a panel discussion titled "The Future of Drug Discovery" on the morning of October 21, from 11:35 AM to 12:15 PM.
As a global leader in AI drug discovery and anti-aging science, Dr. Alex Zhavoronkov will take the stage alongside top leaders from global healthcare systems, life sciences, and investment sectors. The panel will explore how generative AI systematically reshapes the entire chain of target discovery, molecular design, and clinical development, while sharing Insilico Medicine's latest practices in generative AI platforms, aging clock research, and global pipeline layout to present a future vision of AI-driven drug discovery.
About Abu Dhabi Future Health Summit
The Abu Dhabi Future Health Summit is the annual flagship event of "Future Health – A Global Initiative by Abu Dhabi," convened by the Department of Health – Abu Dhabi and held at the Abu Dhabi National Exhibition Centre (ADNEC). Under the theme "To Sense is to Predict," this year's summit focuses on four key impact areas: longevity and precision medicine, digital health and AI, health system resilience and sustainability, and life sciences investment. The event is expected to bring together approximately 16,000 attendees from 100 countries, over 175 exhibiting organizations, and 300 speakers—including global industry leaders such as AstraZeneca CEO Pascal Soriot and Isomorphic Labs President Max Jaderberg—serving as a core international platform for driving global health systems from "disease response" toward "prediction and prevention."
October 23–24, Dubai | Regenerative Medicine Congress 2026
Dr. Alex Aliper, Co-founder and President of Insilico Medicine, has been invited to attend the Regenerative Medicine Congress 2026 in Dubai. He will deliver a speech titled "Generative and Automation AI for Drug Discovery and Longevity" on the afternoon of October 23 at 4:20 PM.
As one of the Middle East's leading industry events in scale and influence within regenerative medicine, this congress gathers top researchers, clinical experts, and innovative enterprises at the forefront of global cell therapy and regenerative medicine. Dr. Alex Aliper will engage in in-depth exchanges with pioneers in the field, sharing Insilico Medicine's scientific insights and platform capabilities across AI-driven drug discovery, aging clocks, anti-aging interventions, and the cutting edges of cellular and regenerative medicine, further expanding the company's global collaboration network in longevity science and regenerative medicine.
About Regenerative Medicine Congress
Marking its 4th edition this year, the Regenerative Medicine Congress is held at the JW Marriott Hotel Marina in Dubai and stands as one of the fastest-growing professional medical gatherings in the Middle East and North Africa (MENA) region. Bringing together over 500 healthcare professionals, biotech leaders, and industry pioneers, the congress covers key application domains such as neurology, cardiology, orthopedics, medical aesthetics, and longevity medicine through keynote speeches, scientific workshops, and strategic networking sessions. It addresses cutting-edge topics including stem cell applications, exosome therapy, gene editing, personalized cell therapy, and AI-powered treatment planning, aiming to advance frontier regenerative science from basic research to clinical application and industrial implementation.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com